Table 1.
Population characteristics.
| All patients (n = 82) |
Acute (n = 28) |
Recovered (n = 54) |
P⁎ | |
|---|---|---|---|---|
| Age, years, mean ± SD | 58.8 ± 13.2 | 62.5 ± 13.6 | 57.3 ± 12.8 | .068 |
| Male, n (%) | 56 (68.3) | 20 (71.4) | 36 (66.7) | .8 |
| Duration from onset, days, mean ± SD | 37.3 ± 23.1 | 7.2 ± 5.0 | 52.2 ± 7.1 | <.001 |
| Duration from discharge, days, mean ± SD | NA | NA | 31.6 ± 9.3 | NA |
| Smoke (current), n (%) | 11 (13.4) | 7 (25.0) | 4 (7.4) | .039 |
| Hypertension, n (%) | 25 (30.5) | 10 (35.7) | 15 (27.8) | .48 |
| Diabetes, n (%) | 9 (11.0) | 7 (25.0) | 2 (3.7) | .006 |
| Rheumatic disease | 4 (4.9) | 3 (10.7) | 1 (1.8) | .11 |
| BMI >25 kg/m2, n (%) | 50 (61.0) | 16 (57.1) | 34 (63.0) | .92 |
| Acral symptomsa, n (%) | 8 (9.8) | 0 (0) | 8 (14.8) | .046 |
| Oxygen therapyb, n (%) | 47 (57.3) | 17 (60.7) | 30 (55.6) | .81 |
| ICU, n (%) | 5 (6.1) | 0 (0) | 5 (9.3) | .16 |
| Anti-IL6R, n (%) | 21 (25.6) | 7 (25.0) | 14 (25.9) | .93 |
| Enoxaparina, n (%) | 39 (47.5) | 24 (85.7) | 15 (25.9) | <.001 |
| PTE or DVT, n (%) | 8 (9.8) | 5 (17.9) | 3 (5.6) | .15 |
SD: standard deviation; BMI: body mass index; ICU: intensive care unit; IL6R: interleukin-6 receptor; PTE: pulmonary thrombo-embolism; DVT: deep vein thrombosis.
Bold is used to highlight a p-value <0.05 which is therefore considered statistically significant.
⁎
P comparisons between acute and recovered patients.
a
Temporally related to COVID-19.
b
During hospitalization.